Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Scaling the manufacture of adipose tissue-derived mesenchymal stromal cells: integrated bioreactor workflows from inoculation to harvest without the need of seed train.

Costa MHG., Terrasso AP., Crespo IE., Valero R., Menéndez B., Painho B.

Laboratory Study on Immune Modulation, published in BMC Biotechnol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
BMC Biotechnol (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41572236
PMCID
PMC12903634
DOI
10.1186/s12896-026-01101-9

Abstract (original English)

BACKGROUND: The production of human mesenchymal stromal cells (hMSC) for therapeutic use requires scalable, efficient and standardized manufacturing processes that could further benefit from shortening manufacturing time, automate and simplify operations with closed systems. This study aimed to develop an industry-ready process for the expansion and integrated downstream processing of human adipose tissue-derived MSC (ASC) using xeno-free medium and microcarriers in stirred-tank bioreactors. The proposed workflow provides controlled culture conditions and is compatible with closed and large-scale cell production. METHODS: ASC were directly inoculated after thawing in stirred-tank bioreactors without the need for a seed train. Microcarrier type (Plastic vs. Synthemax II-coated) in combination with xeno-free medium and stirring profile during cell attachment (intermittent vs. continuous) were optimized in 0.2 L bioreactors and subsequently scaled-up to 2 L bioreactors using power input per volume as scale-up criteria. Focusing on further process scale-up, two strategies were evaluated: (1) bead-to-bead transfer, enabling cell migration from colonized to fresh microcarriers, and (2) enzymatic detachment followed by re-inoculation as single cells. A closed downstream process, using counterflow centrifugation was integrated as an alternative to conventional open centrifugation. RESU

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
BioreactorsMesenchymal Stem CellsBatch Cell Culture TechniquesHumans

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research